// Bilingual content map for the CSG home page.
// Sourced from the CSG May 2026 company profile.

const T = {
  de: {
    eyebrowHero: 'Full-Service CRO · Berlin · athagoras Group',
    h1a: 'Embedded clinical research',
    h1b: 'and real-world studies.',
    heroLede: 'Klein genug, um agil zu sein. Tief genug verwurzelt, um etwas zu bewegen. Groß genug, um jeder Anforderung gerecht zu werden — die persönliche Aufmerksamkeit einer Boutique-CRO, gestützt auf ein Netzwerk von über 500 Expertinnen und Experten.',
    btnPrimary: 'Studie anfragen',
    btnGhost: 'Über CSG',
    pull: '„Flache Hierarchien, direkter Zugang zu Expertise — keine Umwege, keine Verzögerungen. 25 Jahre D-A-CH bedeuten Vertrautheit mit Deutschlands Regulatorik und HTA-Landschaft."',
    pullRole: 'GESCHÄFTSFÜHRUNG',
    pullName: 'Dr. Marc Kurepkat · CEO · IGES Group seit 2001',
    kpis: [
      ['25+', 'Jahre Erfahrung'],
      ['D-A-CH', 'Regionale Expertise'],
      ['1–90', 'Standorte pro Studie'],
      ['500+', 'Experten im Netzwerk'],
      ['2', 'G-BA-Mandate §137e'],
    ],
    ch02: { eyebrow: 'Kernleistungen', title: 'Fünf Disziplinen. Ein integriertes Team.', kicker: 'Vollservice oder FSP — flexibel auf Ihren Bedarf zugeschnitten. Ein dedizierter Project Manager als Single Point of Contact, von Phase II bis zum finalen Clinical Study Report.' },
    ch03: { eyebrow: 'Leistungsspektrum', title: 'Vom Studienkonzept bis Lifecycle Management.', kicker: 'Wir begleiten Ihre Evidenz über den gesamten Produktlebenszyklus — pre- und post-launch, primäre Daten und Real-World Evidence.' },
    ch04: { eyebrow: 'Scope of Services', title: 'Sieben Spezialgebiete. Eine CRO.', kicker: 'MedTech, Pharma, RWE, DiGA, AbD, Erprobungsstudien und ATMP — wir kennen die Akteure, die regulatorischen Pfade und die jeweiligen Erfolgskriterien.' },
    ch05: { eyebrow: 'Pre-Approval Services', title: 'Wie wir Studien aufsetzen.', kicker: 'Vier Etappen vor Studienstart, klare Verantwortlichkeiten, dokumentierte Übergänge — wir adressieren Risiken, bevor sie entstehen.' },
    process: [
      ['Studienkonzept', '01', 'Forschungsfrage · Study Design Selection · RCT · Pragmatic · Observational · RWD · Primary & Secondary Endpoints · SAP & Power Analysis · GCP-, MDR- & IVDR-konform.'],
      ['Protokoll', '02', 'Comprehensive Protocol Writing · Patient Information & Consent · Investigator Brochure · CRFs · IMPD · Medical Writing nach EMA, BfArM & FDA Standards.'],
      ['Regulatory & Ethics', '03', 'BfArM · PEI · EMA · FDA · Scientific Advice · Protocol Assistance · Clinical Trial Application Filing · Ethics Committee Submission · IMPD · Regulatory Roadmap.'],
      ['Patient Recruitment', '04', 'IMC Clinicon Site Analytics · Feasibility-Analysen · Site Identification · realistische Recruitment-Timelines · D-A-CH-CRA-Netzwerk · Competitive Landscape Intelligence.'],
    ],
    ch06: { eyebrow: 'Post-Approval & Lifecycle', title: 'Nach der Zulassung hört unsere Arbeit nicht auf.', kicker: 'Phase IV, PMS, Pharmakovigilanz, Market Access Protection und Real-World Evidence — auch über den Patentablauf hinaus.' },
    cases: [
      ['Phase IV & PMS', 'Post-Market Surveillance · PASS · PAES · NIS · Label Updates', 'Wir begleiten die Nachzulassungsphase mit den passenden Studiendesigns — Real-Life-Daten für Etikettenanpassungen und Indikationserweiterungen.'],
      ['Materiovigilance', 'PMCF · PMS · FSCAs · Vigilance Reporting · PRRC Support · MDR', 'Sicherstellung der MDR-konformen Überwachung mit ISO 14971 — generieren wir die Evidenz für eine nachhaltige Marktposition in Europa.'],
      ['Pharmacovigilance', 'PSUR · PBRER · DSUR · RMP Updates · Signal Detection · QPPV', 'Signalerkennung, periodische Berichte und QPPV-Dienste — Sicherheit als kontinuierlicher Prozess während des gesamten Produktlebens.'],
    ],
    ch07: { eyebrow: 'Why CSG', title: 'Boutique-CRO. Konzern-Power.' },
    differentiator1: 'CSG ist eine in Berlin ansässige Full-Service-CRO, eingebettet in das Expertennetzwerk der athagoras / IGES Group — von der präklinischen Studie über das Inverkehrbringen bis hin zu primären Daten für Real-World Evidence, für Kund:innen aus Pharma, MedTech und der digitalen Welt.',
    differentiator2: 'Flache Hierarchien, direkter Zugang zu Expertise — keine Umwege. Backed by 500+ athagoras-Experten skalieren Teams schnell, wenn das Projekt es erfordert. Über 25 Jahre in der D-A-CH-Region haben tiefe Vertrautheit mit Deutschlands Regulatorik und HTA-Landschaft entstehen lassen.',
    diffPoints: [
      ['Single Point of Contact', 'Ein dedizierter PM für jedes Projekt'],
      ['Full-Service oder FSP', 'Flexibles Engagement nach Ihrem Bedarf'],
      ['Regulatorische Expertise', 'BfArM · PEI · EMA · FDA · G-BA · MDR'],
      ['CRO-Expertise', 'Phase II–IV · CE-Mark §137e · DiGA · AbD · RWD'],
      ['Quality First', 'ICH-GCP E6(R3) · GVP · MDR · GDPR'],
      ['Tief verankert', 'D-A-CH · europäische Perspektive · global kompatibel'],
    ],
    ch08: { eyebrow: 'Team', title: 'Multidisziplinäre Expertise für Ihre Studie.', kicker: 'Erfahrene Spezialist:innen mit 10–30+ Jahren klinischer Forschung — interdisziplinär und kollaborativ aufgestellt über die athagoras Group hinweg.' },
    teamCta: 'Alle Disziplinen',
    teamRoles: [
      ['Project Management', 'PM', 'Single Point of Contact · Multi-Indication-Erfahrung · Timelines & Budget'],
      ['Monitoring', 'CRA', 'GCP-zertifiziertes Site Monitoring · Datenqualitätssicherung · D-A-CH Netzwerk · On-Site Investigator Support'],
      ['Data Management', 'DM', 'Verschiedene EDC-Systeme (z.B. Oracle Clinical) · Database Design & Validation · Datenintegrität · CDISC-Standards'],
      ['Biostatistik', 'BST', 'Statistische Analysepläne (SAP) · SAS/CDISC · Komplexe Datenauswertung · Aussagekräftige Interpretation'],
      ['Regulatory & PV', 'RA', 'Ethikkommissions-Submissions · BfArM · EMA · FDA · QPPV · PV Scientists · Signal Detection · DSUR/PSUR/PBRER'],
    ],
    ch09: { eyebrow: 'IGES Group Ecosystem', title: 'Eingebettet in ein 500+ Experten-Netzwerk.' },
    insights: [
      ['Mutterhaus', 'athagoras Group', 'Strategischer Verbund spezialisierter Beratungs- und Forschungs­unternehmen rund um Gesundheitsversorgung.'],
      ['Forschung & Regulatory', 'IGES Institut · IGES GmbH', 'German Health Research, Regulatorik & PV — Confinis, S-Cubed, DiaMed, CSO Pharma.'],
      ['MedTech & RWE', 'athagoras MedTech · IMC · Quantify', 'Market Access, Real-World Evidence und Site Analytics für Medizinprodukte und Pharma.'],
      ['Pharma & Tech', 'IGES Pharma · MIGx · RCH', 'Pharma Market Access, Health Econ, Ecker & Ecker — und Tech / Data / AI Solutions.'],
    ],
    insightsCta: 'Alle Partner ansehen',
    ch10: { eyebrow: 'Nächster Schritt', title: 'Sprechen wir über Ihre' },
    ctaItalic: 'Studie',
    ctaLede: 'Erstgespräch direkt mit dem Project Manager, der Ihr Projekt führen wird — typischerweise 30 Minuten, vertraulich, ohne Verpflichtung.',
    ctaBtn: 'Termin anfragen',
    locations: [['Berlin', 'Hauptsitz', 'Clinische Studiengesellschaft mbH\nBerlin, Deutschland'], ['athagoras Group', 'Network', '500+ Expert:innen\nD-A-CH · Europa'], ['IGES Institut', 'Health Research', 'German Health Research\nseit 1980']],
    certs: ['ICH-GCP E6 (R3)', 'GVP', 'MDR / IVDR', 'GDPR / DSGVO', 'GAMP 5', 'FDA 21 CFR Part 11', 'EU Annex 11', 'ISO 14971'],
    services: SERVICES.map(s => ({ ...s })),
    sectorsLoc: SECTORS.map(s => s.desc),
  },
  en: {
    eyebrowHero: 'Full-Service CRO · Berlin · athagoras Group',
    h1a: 'Embedded clinical research',
    h1b: 'and real-world studies.',
    heroLede: 'Small enough to be agile. Rooted deep enough to matter. Large enough to handle anything it requires — the personal attention of a boutique CRO, backed by a network of 500+ experts.',
    btnPrimary: 'Request a study',
    btnGhost: 'About CSG',
    pull: '"Flat hierarchies, direct access to experts — no detours, no delays. Over 25 years in D-A-CH mean deep familiarity with Germany\u2019s regulatory and HTA landscape."',
    pullRole: 'MANAGEMENT',
    pullName: 'Dr. Marc Kurepkat · CEO · IGES Group since 2001',
    kpis: [
      ['25+', 'Years of experience'],
      ['D-A-CH', 'Regional expertise'],
      ['1–90', 'Sites per study'],
      ['500+', 'Experts in the network'],
      ['2', 'G-BA mandates §137e'],
    ],
    ch02: { eyebrow: 'Core services', title: 'Five disciplines. One integrated team.', kicker: 'Full-service or FSP — flexible engagement tailored to your needs. A dedicated Project Manager as Single Point of Contact, from Phase II through the final Clinical Study Report.' },
    ch03: { eyebrow: 'Scope of services', title: 'From study concept through lifecycle management.', kicker: 'We support your evidence across the entire product lifecycle — pre- and post-launch, primary data and real-world evidence.' },
    ch04: { eyebrow: 'Specialisations', title: 'Seven focus areas. One CRO.', kicker: 'MedTech, Pharma, RWE, DiGA, AbD, Erprobungsstudien and ATMP — we know the players, the regulatory paths, and the success criteria of each.' },
    ch05: { eyebrow: 'Pre-approval services', title: 'How we set studies up.', kicker: 'Four stages before study start, clear ownership, documented handoffs — we address risks before they materialise.' },
    process: [
      ['Study Concept', '01', 'Research question · study design selection · RCT · pragmatic · observational · RWD · primary & secondary endpoints · SAP & power analysis · GCP, MDR & IVDR compliance.'],
      ['Protocol', '02', 'Comprehensive protocol writing · patient information & consent · investigator brochure · CRFs · IMPD · medical writing to EMA, BfArM & FDA standards.'],
      ['Regulatory & Ethics', '03', 'BfArM · PEI · EMA · FDA · scientific advice · protocol assistance · clinical trial application filing · ethics committee submission · IMPD · regulatory roadmap.'],
      ['Patient Recruitment', '04', 'IMC Clinicon site analytics · feasibility analysis · site identification · realistic recruitment timelines · D-A-CH CRA network · competitive landscape intelligence.'],
    ],
    ch06: { eyebrow: 'Post-approval & lifecycle', title: 'Our work doesn\u2019t end at market approval.', kicker: 'Phase IV, PMS, pharmacovigilance, market-access protection and real-world evidence — well beyond patent expiry.' },
    cases: [
      ['Phase IV & PMS', 'Post-Market Surveillance · PASS · PAES · NIS · Label Updates', 'We accompany the post-approval phase with the right study designs — real-life data for label updates and indication expansion.'],
      ['Materiovigilance', 'PMCF · PMS · FSCAs · Vigilance Reporting · PRRC Support · MDR', 'MDR-compliant surveillance with ISO 14971 — generating the evidence required for sustained market positioning in Europe.'],
      ['Pharmacovigilance', 'PSUR · PBRER · DSUR · RMP Updates · Signal Detection · QPPV', 'Signal detection, periodic reporting and QPPV services — safety as a continuous process throughout the product lifecycle.'],
    ],
    ch07: { eyebrow: 'Why CSG', title: 'Boutique CRO. Group-scale power.' },
    differentiator1: 'CSG is a Berlin-based Full-Service CRO embedded within the 500+ expert network of the athagoras / IGES Group — spanning pre- and post-launch studies and primary data for real-world evidence, for clients from Pharma, MedTech and the digital world.',
    differentiator2: 'Flat hierarchies, direct access to experts — no detours. Backed by 500+ athagoras experts, teams scale quickly when projects demand it. Over 25 years in the D-A-CH region have built deep familiarity with Germany\u2019s regulatory and HTA landscape.',
    diffPoints: [
      ['Single Point of Contact', 'One dedicated PM for every project'],
      ['Full-Service or FSP', 'Flexible engagement tailored to your needs'],
      ['Regulatory Expertise', 'BfArM · PEI · EMA · FDA · G-BA · MDR'],
      ['CRO Expertise', 'Phase II–IV · CE-Mark §137e · DiGA · AbD · RWD'],
      ['Quality First', 'ICH-GCP E6(R3) · GVP · MDR · GDPR'],
      ['Firmly anchored', 'D-A-CH · European perspective · global compatible'],
    ],
    ch08: { eyebrow: 'Team', title: 'Multidisciplinary expertise for your study.', kicker: 'Experienced specialists with 10–30+ years in clinical research — interdisciplinary and collaborative across the athagoras Group.' },
    teamCta: 'All disciplines',
    teamRoles: [
      ['Project Management', 'PM', 'Single Point of Contact · multi-indication experience · timelines & budget oversight'],
      ['Monitoring', 'CRA', 'GCP-certified site monitoring · data quality assurance · D-A-CH regional network · on-site investigator support'],
      ['Data Management', 'DM', 'Various EDC systems (e.g. Oracle Clinical) · database design & validation · data integrity · CDISC standards'],
      ['Biostatistics', 'BST', 'Statistical analysis plans (SAP) · SAS/CDISC · complex data evaluation · meaningful interpretation of results'],
      ['Regulatory & PV', 'RA', 'Ethics committee submissions · BfArM · EMA · FDA · QPPV · PV scientists · signal detection · DSUR/PSUR/PBRER'],
    ],
    ch09: { eyebrow: 'IGES Group ecosystem', title: 'Embedded in a 500+ expert network.' },
    insights: [
      ['Group parent', 'athagoras Group', 'A strategic federation of specialised consulting and research companies around healthcare delivery.'],
      ['Research & Regulatory', 'IGES Institut · IGES GmbH', 'German Health Research, regulatory & PV — Confinis, S-Cubed, DiaMed, CSO Pharma.'],
      ['MedTech & RWE', 'athagoras MedTech · IMC · Quantify', 'Market access, real-world evidence and site analytics for medical devices and pharma.'],
      ['Pharma & Tech', 'IGES Pharma · MIGx · RCH', 'Pharma market access, health econ, Ecker & Ecker — and Tech / Data / AI Solutions.'],
    ],
    insightsCta: 'See all partners',
    ch10: { eyebrow: 'Next step', title: 'Let us talk about your' },
    ctaItalic: 'study',
    ctaLede: 'A first call directly with the Project Manager who will later run your project — typically 30 minutes, confidential, no commitment.',
    ctaBtn: 'Request a call',
    locations: [['Berlin', 'Headquarters', 'Clinische Studiengesellschaft mbH\nBerlin, Germany'], ['athagoras Group', 'Network', '500+ experts\nD-A-CH · Europe'], ['IGES Institut', 'Health research', 'German health research\nsince 1980']],
    certs: ['ICH-GCP E6 (R3)', 'GVP', 'MDR / IVDR', 'GDPR', 'GAMP 5', 'FDA 21 CFR Part 11', 'EU Annex 11', 'ISO 14971'],
    services: SERVICES.map(s => ({ ...s, name: s.en, desc: ({
      studyconcept: 'From research question to submission-ready concept — feasibility, study design, SAP and a regulatory strategy for BfArM, EMA, FDA or ethics committees, set together from day one.',
      pm: 'Single Point of Contact for all study activities — sites, vendors, authorities. Flat hierarchies, fast decisions. From Phase II through the final Clinical Study Report.',
      monitoring: 'On-site SDV, remote EDC review and risk-based monitoring per ICH-GCP E6(R3). The D-A-CH CRA network speaks the local language and understands German clinical workflows.',
      dm: 'Electronic Data Capture (e.g. Oracle Clinical RDC), paper-based CRF, hybrid approaches, ePRO and eDiary. CDISC-compliant SDTM and ADaM datasets — submission-ready.',
      stats: 'Built in early, not bolted on late: sample size, randomisation and SAP from the first protocol discussion. SAS® programming, CDISC-compliant TLFs for your Clinical Study Report.',
    })[s.key] })),
    sectorsLoc: [
      'MDR- and IVDR-compliant clinical investigations and performance studies — pre-launch pivotal studies for CE marking, post-launch PMCF, PMS and materiovigilance.',
      'Phase II/III pre-approval with PV (SAE, SUSAR, RMP, DSMB) and post-approval NIS, PASS, Phase IV — including registry operation and health-services research.',
      'Primary and secondary data, NIS, PASS, PMS, chart reviews, ePRO/eDiary. Established networks of physicians and clinics across D-A-CH — answers from real-world care.',
      'One of the first CROs in Germany specialised in DiGA. From clinical evidence (positiver Versorgungseffekt) through BfArM Fast-Track to permanent listing under §139e SGB V.',
      'Anwendungsbegleitende Datenerhebung under §35a SGB V — protocols & SAPs aligned with G-BA/IQWiG, eCRF for real-world data, qualified monitoring of registry data.',
      'The G-BA pathway under §137e SGB V toward statutory health-insurance reimbursement of medical devices. Two G-BA-mandated studies on our record — from protocol to final report.',
      'Advanced Therapy Medicinal Products — gene, cell and tissue therapies. Early clinical development, Phase II/III, logistics for living cells and viral vectors, long-term follow-up.',
    ],
  },
};

window.T_HYBRID = T;